ATE145556T1 - Verwendung von interleukin-4 zur behandlung der festen tumoren - Google Patents
Verwendung von interleukin-4 zur behandlung der festen tumorenInfo
- Publication number
- ATE145556T1 ATE145556T1 AT91918403T AT91918403T ATE145556T1 AT E145556 T1 ATE145556 T1 AT E145556T1 AT 91918403 T AT91918403 T AT 91918403T AT 91918403 T AT91918403 T AT 91918403T AT E145556 T1 ATE145556 T1 AT E145556T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- solid tumors
- interleukin
- date mar
- treat solid
- Prior art date
Links
- 108090000978 Interleukin-4 Proteins 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 102000004388 Interleukin-4 Human genes 0.000 title 1
- 229940028885 interleukin-4 Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 101100069857 Caenorhabditis elegans hil-4 gene Proteins 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57896890A | 1990-09-06 | 1990-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE145556T1 true ATE145556T1 (de) | 1996-12-15 |
Family
ID=24315064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91918403T ATE145556T1 (de) | 1990-09-06 | 1991-09-03 | Verwendung von interleukin-4 zur behandlung der festen tumoren |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5382427A (de) |
| EP (1) | EP0552243B1 (de) |
| JP (1) | JPH06501017A (de) |
| KR (1) | KR100229974B1 (de) |
| AT (1) | ATE145556T1 (de) |
| AU (1) | AU661979B2 (de) |
| CA (1) | CA2091170A1 (de) |
| DE (1) | DE69123361T2 (de) |
| DK (1) | DK0552243T3 (de) |
| GR (1) | GR3022321T3 (de) |
| HU (1) | HU215389B (de) |
| WO (1) | WO1992004044A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0490006B1 (de) * | 1990-12-13 | 1994-06-22 | Schering-Plough | Pharmazeutische Zusammensetzungen zur Behandlung von bösartigen B-Zellenkrankheiten |
| US5679338A (en) * | 1994-05-12 | 1997-10-21 | Osteoarthritis Science, Inc. | Use of IL-4 for inhibition of the breakdown of articular cartilage and other tissues |
| US6576236B1 (en) * | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
| US20020127201A1 (en) * | 1994-07-01 | 2002-09-12 | Dana-Farber Cancer Institute. | Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain |
| US5716612A (en) * | 1994-09-07 | 1998-02-10 | Schering Corporation | Use of IL-4 for potentiation of chemotherapeutic agents |
| US20080220025A1 (en) * | 1995-03-17 | 2008-09-11 | James Thompson | Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells |
| JP3201610B2 (ja) * | 1995-03-17 | 2001-08-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 腫瘍を処置する方法 |
| US7361332B2 (en) * | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
| US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| RU2115429C1 (ru) * | 1997-07-22 | 1998-07-20 | Закрытое акционерное общество "Фосфосорб" | Рекомбинантный иммунотоксин на основе дифтерийного токсина и интерлейкина-2 (дт 482-il2) и способ его получения |
| US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| CA2333147C (en) * | 1998-07-13 | 2012-02-07 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| US7067109B1 (en) * | 1998-07-13 | 2006-06-27 | Board Of Regents, The University Of Texas System | Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids |
| US6362162B1 (en) | 1999-04-08 | 2002-03-26 | Schering Corporation | CML Therapy |
| US6923966B2 (en) * | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
| US6605273B2 (en) | 1999-04-08 | 2003-08-12 | Schering Corporation | Renal cell carcinoma treatment |
| US7285414B2 (en) * | 2000-09-26 | 2007-10-23 | Emory University | Viruses targeted to hypoxic cells and tissues |
| US20040101825A1 (en) * | 2001-09-26 | 2004-05-27 | Van Meir Erwin G. | Viruses targeted to hypoxic cells and tissues |
| JP2004536800A (ja) * | 2001-05-09 | 2004-12-09 | アルカベロ アクチェセルスカプ | Th1/th2比を変調することによりth1及びth2細胞関連疾患を予防又は治療するための医薬組成物 |
| EP4285913A1 (de) * | 2022-05-30 | 2023-12-06 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Hochwirksame adoptive t-zelltherapie |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0302429B1 (de) * | 1987-08-03 | 1993-07-28 | Tasuku Honjo | Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten |
| US4958007A (en) * | 1988-05-17 | 1990-09-18 | Schering-Plough Corp. | Extraction of human interleukin-4- from bacteria |
-
1991
- 1991-09-03 WO PCT/US1991/006126 patent/WO1992004044A1/en not_active Ceased
- 1991-09-03 AT AT91918403T patent/ATE145556T1/de not_active IP Right Cessation
- 1991-09-03 HU HU9300624A patent/HU215389B/hu not_active IP Right Cessation
- 1991-09-03 EP EP91918403A patent/EP0552243B1/de not_active Expired - Lifetime
- 1991-09-03 JP JP3517814A patent/JPH06501017A/ja active Pending
- 1991-09-03 DK DK91918403.6T patent/DK0552243T3/da active
- 1991-09-03 CA CA002091170A patent/CA2091170A1/en not_active Abandoned
- 1991-09-03 KR KR1019930700675A patent/KR100229974B1/ko not_active Expired - Fee Related
- 1991-09-03 AU AU88505/91A patent/AU661979B2/en not_active Ceased
- 1991-09-03 US US07/984,414 patent/US5382427A/en not_active Expired - Fee Related
- 1991-09-03 DE DE69123361T patent/DE69123361T2/de not_active Expired - Fee Related
-
1997
- 1997-01-21 GR GR970400085T patent/GR3022321T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US5382427A (en) | 1995-01-17 |
| HU215389B (hu) | 1998-12-28 |
| EP0552243B1 (de) | 1996-11-27 |
| CA2091170A1 (en) | 1992-03-07 |
| DK0552243T3 (da) | 1997-03-10 |
| DE69123361T2 (de) | 1997-04-30 |
| JPH06501017A (ja) | 1994-01-27 |
| GR3022321T3 (en) | 1997-04-30 |
| AU8850591A (en) | 1992-03-30 |
| WO1992004044A1 (en) | 1992-03-19 |
| DE69123361D1 (de) | 1997-01-09 |
| EP0552243A1 (de) | 1993-07-28 |
| AU661979B2 (en) | 1995-08-17 |
| HUT63769A (en) | 1993-10-28 |
| KR100229974B1 (ko) | 1999-11-15 |
| HU9300624D0 (en) | 1993-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE145556T1 (de) | Verwendung von interleukin-4 zur behandlung der festen tumoren | |
| DE69424915D1 (de) | Verwendung von 1-2-4-Benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren | |
| ATE139447T1 (de) | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen | |
| RU94031102A (ru) | Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний | |
| ATE232394T1 (de) | Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs | |
| ATE174218T1 (de) | Verwendung von leflunomid zur hemmung von interleukin 1 beta | |
| ATE71662T1 (de) | Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung. | |
| GB8805792D0 (en) | Medicaments | |
| ATE143260T1 (de) | Verwendung von (s)-isofluran und (s)-desfluran zur anästhesie sowie entsprechende arzneimittelzubereitungen | |
| DE69316013D1 (de) | Verwendung von phosphinate zur behandlung der osteoporose | |
| DE59407414D1 (de) | Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha | |
| ATE220923T1 (de) | Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen | |
| ATE107168T1 (de) | Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression. | |
| ATE174629T1 (de) | Herstellung von proteinen mittels protein 7b2 | |
| DE69732616D1 (de) | Erhöhung der Migration oder Proliferation von Keratinocyten | |
| DE69021257D1 (de) | Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL. | |
| DE69924483D1 (de) | Kombinationstherapie zur behandlung von tumoren | |
| ATE157010T1 (de) | Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen | |
| ATE174220T1 (de) | Verwendung von leflunomid zur hemmung von interleukin 8 | |
| ATE59780T1 (de) | Pharmazeutische zusammensetzung zur behandlung von tumoren. | |
| DE69528473D1 (de) | Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen | |
| DE3881703D1 (de) | Behandlung zur verbesserung der eigenschaften von keratintextilmaterialien. | |
| ATE178336T1 (de) | Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis | |
| ATE135232T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen | |
| ATE174217T1 (de) | Verwendung von leflunomid zur hemmung von interleukin 1 alpha |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |